Haemonetics (STU:HAZ) Inventories, Finished Goods : €154 Mil (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Haemonetics Inventories, Finished Goods?

Haemonetics's quarterly finished goods increased from Sep. 2023 (€130 Mil) to Dec. 2023 (€138 Mil) and increased from Dec. 2023 (€138 Mil) to Mar. 2024 (€154 Mil).

Haemonetics's annual finished goods declined from Mar. 2022 (€180 Mil) to Mar. 2023 (€123 Mil) but then increased from Mar. 2023 (€123 Mil) to Mar. 2024 (€154 Mil).

Haemonetics Inventories, Finished Goods Historical Data

The historical data trend for Haemonetics's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Haemonetics Inventories, Finished Goods Chart

Haemonetics Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Inventories, Finished Goods

Get a 7-Day Free Trial

165.06

188.66

179.78

123.09

154.16

Haemonetics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Inventories, Finished Goods	Get a 7-Day Free Trial															123.09	132.43	129.84	138.09	154.16

Haemonetics Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

Haemonetics (STU:HAZ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Haemonetics Corp (STU:HAZ) » Definitions » Inventories, Finished Goods

Comparable Companies

Traded in Other Exchanges

HAE:USA

Address

125 Summer Street, Boston, MA, USA, 02110

Website

https://www.haemonetics.com

Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.

Haemonetics (STU:HAZ) Headlines

No Headlines